Deboever Nathaniel, Eisenberg Michael, Chidi Alexis, Sepesi Boris
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Surg Oncol. 2023 Feb;127(2):275-281. doi: 10.1002/jso.27166.
As the immunotherapeutic milieu in resectable nonsmall cell lung cancer continues to evolve, the field of thoracic oncology actively moves towards better patient selection based on biomarkers and oncogenic drivers. In this article, we review the current standard of oncologic care in this population and discuss the ongoing phase III clinical trials investigating the use of immunotherapy or targeted therapy in the perioperative period. We also discuss genotyping initiatives, biomarkers, and trial endpoints.
随着可切除非小细胞肺癌免疫治疗环境的不断演变，胸肿瘤学领域正积极朝着基于生物标志物和致癌驱动因素进行更好的患者选择发展。在本文中，我们回顾了该人群当前的肿瘤治疗标准，并讨论了正在进行的关于围手术期使用免疫疗法或靶向疗法的III期临床试验。我们还讨论了基因分型计划、生物标志物和试验终点。
